Ftse Mib
34.799,27
-0,83%
DAX
20.132,85
-0,44%
S&P 500
5.836,22
0,16%
NASDAQ
19.088,10
-0,38%
Bitcoin
94.841,90
0,35%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ChromaDex Corporation (CDXC) ChromaDex Corporation (CDXC) Notizie

ChromaDex Corporation

CDXC
5,31
0,04 (0,76%)
14 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
06/1/202514:32BWChromaDex to Participate in the Lytham Partners 2025..
16/12/202422:00EDGAR2Form 8-K - Current report
14/12/202401:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202419:54EDGAR2Form 144 - Report of proposed sale of securities
04/12/202423:26EDGAR2Form 8-K - Current report
03/12/202414:34BWChromaDex Named to the Inc. 2024 Best in Business List in..
25/11/202413:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202423:20EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
21/11/202422:01EDGAR2Form 8-K - Current report
14/11/202414:32BWChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient,..
08/11/202422:47EDGAR2Form 3 - Initial statement of beneficial ownership of..
07/11/202414:32BWChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible..
31/10/202421:04BWChromaDex Corporation Reports Third Quarter 2024 Financial..
31/10/202421:01EDGAR2Form 8-K - Current report
31/10/202421:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
28/10/202413:32BWChromaDex to Report Third Quarter 2024 Financial Results on..
24/10/202414:32BWChromaDex to Report Third Quarter 2024 Financial Results on..
23/10/202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/10/202423:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
23/10/202414:34BWChromaDex to Participate in the 17th Annual LD Micro Main..
15/10/202414:32BWYasmeen Nkrumah-Elie, Ph.D., Global Director of External..
11/10/202422:00EDGAR2Form 8-K - Current report
26/9/202422:12BWChromaDex to Participate in a Fireside Chat at the Lytham..
20/9/202414:32EDGAR2Form 8-K - Current report
20/9/202414:32BWChromaDex Appoints Ozan Pamir as Chief Financial Officer
10/9/202414:32BWChromaDex Announces Expansion of Pharmaceutical-Grade..
09/9/202414:34BWChromaDex Celebrates 25 Years of Innovation and Pioneering..
27/8/202401:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202417:52EDGAR2Form 144 - Report of proposed sale of securities
23/8/202414:34BWChromaDex to Participate in Renmark’s Virtual Non-Deal..
21/8/202412:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202412:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202412:06EDGAR2Form SC 13D/A - General Statement of Acquisition of..
21/8/202412:05EDGAR2Form SC 13D/A - General Statement of Acquisition of..
19/8/202414:32BWChromaDex Secures U.S. Patent for the Composition of Matter..
07/8/202422:04BWChromaDex Corporation Reports Second Quarter 2024 Financial..
07/8/202422:02EDGAR2Form 8-K - Current report
07/8/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/8/202414:32BWChromaDex to Present at Canaccord Genuity’s 44th Annual..
26/7/202422:52EDGAR2Form 3 - Initial statement of beneficial ownership of..
24/7/202414:34BWChromaDex to Report Second Quarter 2024 Financial Results on..
23/7/202414:32BWChromaDex Launches Niagen+ NAD+ Test Kit Available..
22/7/202414:34BWChromaDex Appoints Carlos Lopez as Senior Vice President,..
16/7/202422:00EDGAR2Form 8-K - Current report
16/7/202414:34BWChromaDex Announces Pharmaceutical-Grade Intravenous and..
01/7/202414:32BWChromaDex to Join Russell 2000® Index
24/6/202414:32BWMilestone Phase II Clinical Study Demonstrates Niagen®,..
13/6/202414:32BWChromaDex to Launch Niagen+, the First-Of-Its-Kind..
07/6/202414:34BWChromaDex Receives Exclusive U.S. FDA Orphan Drug..
04/6/202414:32BWChromaDex to Participate in Renmark’s Virtual Non-Deal..
Apertura: 5,23 Min: 5,17 Max: 5,52
Chiusura: 5,27

La tua Cronologia

NASDAQ
CDXC
ChromaDex
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network